Industry Posters (Non-CE) 

Sunday, March 17, 2024

6:15-6:30 pm MDT

Title: Nursing Insights for Seizure Cluster Care in Epilepsy: Shorter Time to Treatment with Diazepam Nasal Spral Is Associated with Faster Time to Termination
View the Poster
Presented by: Neurelis, Inc. 

6:30-6:45 pm MDT

Title: The Huntington’s Disease Health Index (HD-HI): Measuring Changes in Disease Burden in Response to Valbenazine During the KINECT®-HD Trial
View the Poster
Presented by: Neurocrine Biosciences, Inc. 

6:45-7:00 pm MDT

Title: Caregiver-Reported Seizure Outcomes With Real-World Use of Cannabidiol in Tuberous Sclerosis Complex: Interim Results From the BECOME-TSC Survey
View the Poster
Presented by: Jazz Pharmaceuticals, Inc. 

7:00-7:15 pm MDT

Title: Intravenous ganaxolone for the treatment of refractory status epilepticus: results from an open-label, dose-finding, phase 2 trial
View the Poster
Presented by: Marinus Pharmaceuticals, Inc. 

7:15-7:30 pm MDT

Title: Ganaxolone Significantly Reduces Major Motor Seizures Associated with CDKL5 Deficiency Disorder and Demonstrates Sustained Seizure Control Over 2 Years
View the Poster
Presented by: Marinus Pharmaceuticals, Inc. 

Monday, March 18, 2024

9:35-9:50 am MDT

Title: Anticholinergics are Not Appropriate Treatments for Tardive Dyskinesia: Insights from an Expert Panel of Psychiatry and Neurology Healthcare Professionals
View the Poster
Presented by: Neurocrine Biosciences, Inc. 

12:00-12:15 pm MDT

Title: Caregiver-Reported Nonseizure Outcomes With Real-World Use of Cannabidiol in Tuberous Sclerosis Complex: Interim Results From the BECOME-TSC Survey
View the Poster
Presented by: Jazz Pharmaceuticals, Inc.